

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7170132

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
SAOL INTERNATIONAL LIMITED	02/09/2022
SAOL INTERNATIONAL DEVELOPMENT LIMITED	02/09/2022
SAOL INTERNATIONAL RESEARCH LIMITED	02/09/2022
SAOL THERAPEUTICS RESEARCH LIMITED	02/09/2022

**RECEIVING PARTY DATA**

<b>Name:</b>	AMNEAL PHARMACEUTICALS LLC
<b>Street Address:</b>	400 CROSSING BOULEVARD, 3RD FLOOR
<b>City:</b>	BRIDGEWATER
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	08807

**PROPERTY NUMBERS Total: 16**

Property Type	Number
Patent Number:	10434248
Patent Number:	10076506
Patent Number:	9597304
Patent Number:	9180108
Patent Number:	10420740
Patent Number:	10813900
Patent Number:	10792262
Application Number:	62541904
Application Number:	16637114
Application Number:	17630297
Application Number:	17489343
Application Number:	17525298
Application Number:	17041886
PCT Number:	US2018045516
PCT Number:	US2019023891
PCT Number:	US2020034840

**CORRESPONDENCE DATA****Fax Number:** (703)716-1180*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** 17037161191**Email:** gbpatent@gbpatent.com**Correspondent Name:** GREENBLUM & BERNSTEIN, P.L.C.**Address Line 1:** 1950 ROLAND CLARKE PLACE**Address Line 4:** RESTON, VIRGINIA 20191**ATTORNEY DOCKET NUMBER:** J772101**NAME OF SUBMITTER:** ROBERT W. MUELLER**SIGNATURE:** /Robert W. Mueller/**DATE SIGNED:** 02/10/2022**Total Attachments: 13**

source=J772101\_Assignment#page1.tif  
source=J772101\_Assignment#page2.tif  
source=J772101\_Assignment#page3.tif  
source=J772101\_Assignment#page4.tif  
source=J772101\_Assignment#page5.tif  
source=J772101\_Assignment#page6.tif  
source=J772101\_Assignment#page7.tif  
source=J772101\_Assignment#page8.tif  
source=J772101\_Assignment#page9.tif  
source=J772101\_Assignment#page10.tif  
source=J772101\_Assignment#page11.tif  
source=J772101\_Assignment#page12.tif  
source=J772101\_Assignment#page13.tif

## PATENT ASSIGNMENT AGREEMENT

This Patent Assignment Agreement (this “Agreement”) is made effective February 9, 2022, by and among Saol International Limited, a Bermuda limited company (“SIL”), Saol International Development Limited, a Bermuda limited company (“SIDL”), Saol International Research Limited, a Bermuda limited company (“SIRL”), Saol Therapeutics Research Limited, an Irish limited company (“STRL” and collectively with SIL, SIDL and SIRL “Assignors” and each individually, an “Assignor”), and Amneal Pharmaceuticals LLC, a Delaware limited liability company (“Assignee”). Assignors and Assignee are each referred to herein as a “Party” and collectively herein as the “Parties.”

### RECITALS

A. Pursuant to that certain Asset Purchase Agreement (as amended, the “Asset Purchase Agreement”), dated as of December 30, 2021, by and among Assignors, Saol Therapeutics Research Limited, an Irish limited company (“STRL”), Saol Therapeutics Inc., a Delaware corporation (“STI”), Emerald International Limited, a Bermuda limited company (“Emerald”), Emerald Therapeutics Research Limited, an Irish limited company (“ETRL” and, collectively with SIL, STRL, STI, SIRL, SIDL and Emerald, “Sellers” and each, individually, a “Seller”), and Assignee, as amended by that certain Letter Agreement, dated as of February 9, 2022, Sellers agreed to assign or cause their respective Affiliates to assign the Acquired Intellectual Property to Assignee, including the Patent Rights set forth on Exhibit A hereto and the associated rights set forth in Paragraph 2 below (collectively, “Assigned Patent Rights”).

B. The execution and delivery of this Agreement is a requirement under the Asset Purchase Agreement.

**NOW, THEREFORE**, in consideration of the premises set forth above and in the Asset Purchase Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1. Definitions. All capitalized terms used but not defined herein shall have the meanings ascribed to them in the Asset Purchase Agreement. The following terms shall have the meanings set forth in this Section 1:

a. “Acquired Intellectual Property” has the meaning set forth in the Asset Purchase Agreement.

b. “Commercialize” shall mean to promote, market, distribute, sell, offer for sale, have sold and provide product support for the Product pursuant to an NDA approved by the FDA, and “Commercializing” and “Commercialization” shall have correlative meanings.

c. “Exploitation”, and related terms such as “Exploit”, shall mean the research, development, Manufacture, testing, storage, import, export, distribution, sale, use, licensing, advertising, marketing and promotion of the Products and other Commercialization, including the outsourcing of any of the foregoing activities.

d. “Improvement” shall mean any and all improvements and enhancements, patentable or otherwise, related to a Product including, without limitation, in the manufacture, formulation, ingredients, preparation, presentation, means of delivery or administration, dosage, indication, use or packaging of Product or its active ingredient.

e. “Intellectual Property” means collectively, all rights of any nature or kind in any of the following in any jurisdiction throughout the world: (a) Patent Rights, registered trademarks and service marks and applications therefor, Internet domain name registrations and copyright registrations and applications therefor (collectively, “Registered IP”); (b) unregistered trademarks and service marks, trade names, domain names, social media names, “tags,” and “handles”, trade dress, product configurations or other marks, names, logos and slogans embodying business or product goodwill or indications of origin, all translations, adaptations, derivations and combinations thereof, and all goodwill associated with the businesses in which the foregoing are used; (c) inventions and discoveries, whether patentable or unpatentable, whether or not memorized in an invention disclosure, and whether or not reduced to practice, including articles of manufacture, business methods, compositions of matter, improvements, machines, methods, and processes and new uses for any of the preceding items, all improvements thereto; (d) unregistered copyrights, designs, mask works or other expressions and works of authorship and derivative works and translations thereof, all moral rights and visual artists’ rights in relation to the foregoing and to registered copyrights and applications therefor, (e) the right of privacy or publicity, and (f) trade secrets and know-how meeting the definition of a trade secret under the Uniform Trade Secrets Act (collectively, “Trade Secrets”) and all other Know-How.

f. “Know-How” shall mean all technical, scientific and other know-how and information, Trade Secrets, knowledge, technology, means, methods, processes, practices, formulas, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other material, including high-throughput screening and other drug discovery and development technology, pre-clinical and clinical trial results, manufacturing procedures, test procedures and purification and isolation techniques, (whether or not confidential, proprietary, patented or patentable) in written, electronic or any other form now known or hereafter developed, and all improvements, whether to the foregoing or otherwise, and other discoveries, developments, inventions, and other intellectual property (whether or not confidential, proprietary, patented or patentable).

g. “Lioresal” shall mean the Product marketed by Sellers under the brand name Lioresal®, as further described on Exhibit B.

h. “Lyvispah” shall mean the Product developed by Sellers with the brand name Lyvispah®, as further described on Exhibit B.

i. “Manufacture” and “Manufacturing” shall mean all activities related to the production, manufacture, processing, filling, finishing, packaging, labeling, and shipping and holding (prior to distribution) of the Product or any intermediate thereof, including quality assurance and quality control.

j. “Patent Rights” means: (i) all patents, patent applications (including provisional applications), statutory invention registrations, utility models, inventors’ certificates in any country or supranational jurisdiction worldwide; and (ii) any substitutions, divisionals, continuations, continuations-in-part, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates, and the like of any such patents or patent applications.

k. “Products” means (i) Lioresal and Lyvispah and (ii) the pharmaceutical product under development by Assignors and their Affiliates under the name “SIL-1006”, in each case of clauses (i) and (ii), as more specifically described on Exhibit B. Products shall include (i) any Improvements to any Product referred to in the preceding sentence of this definition, including any authorized generic version of any such Product and (ii) any product sold pursuant to the Baclofen ANDA.

2. Assignment. Each Assignor hereby assigns, conveys, sells, and transfers unto Assignee and its successors and assigns, such Assignor’s entire right, title and interest in, to and under the Assigned Patent Rights, including patents and patent applications set forth on Exhibit A hereto and (i) all applications for Letters Patent which may hereafter be filed in the United States of America (“U.S.”) or any foreign country, which, directly or indirectly, incorporate or are derived from the foregoing; (ii) all substitutions, divisionals, continuations, continuations-in-part, reissues, renewals, registrations, confirmations, reexaminations, extensions, supplementary protection certificates, and the like of the foregoing in the U.S. and any foreign jurisdiction; (iii) all Letters Patent worldwide which may be granted from any of the foregoing; (iv) all rights to claim priority on the basis of patents and patent applications set forth on Exhibit A under the patent laws of the United States of America, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed; (v) any and all rights of renewal relating thereto, and (vi) all past, present or existing, and future claims, causes of action, rights of recovery and rights of set-off of any kind (including the right to sue and recover for infringements or misappropriations) against any Person related to or arising from the Assigned Patent Rights in the U.S. and worldwide, and Assignee does hereby accept the foregoing assignment from each Assignor.

3. Authorization. Each Assignor hereby authorizes the Director of the United States Patent and Trademark Office (“USPTO”) and the empowered official of any other Governmental Authority in any jurisdiction foreign to the U.S., whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid and to record patent registrations and applications, to record the transfer of the Assigned Patent Rights, including Patents and Patent Applications set forth on Exhibit A, from Assignor to Assignee and record same as the property of Assignee.

4. Assistance. The Assignor further agrees, at the request of the Assignee, to sign, execute, verify and acknowledge any documents and to do all other things which may be necessary to give effect to the assignment under this Agreement as soon as reasonably practicable and to vest in the Assignee the full title to the Patents, including enabling the Assignee to record its assignment in the records of the USPTO and in the records of any other Governmental Authority in any other jurisdiction.

5. Asset Purchase Agreement Controls. Nothing express or implied in this Agreement shall in any way supersede, modify, replace, amend, change, rescind, waive, limit, exceed, expand, enlarge or in any way affect the provisions, including warranties, covenants, agreements, conditions, representations or rights and remedies, or any of the obligations of Sellers or Buyer set forth in the Asset Purchase Agreement. In the event of any conflict or inconsistency between this Agreement and the Asset Purchase Agreement, the terms of the Asset Purchase Agreement shall govern and control.

6. Miscellaneous.

- (a) Governing Law. This Agreement shall be governed by the Laws of the State of Delaware (without giving effect to any laws, rules or provisions of the State of Delaware that would cause the application of the laws, rules or provisions of any jurisdiction other than the State of Delaware) as to all matters, including matters of validity, construction, effect, performance and remedies. IN THE EVENT ANY PARTY TO THIS AGREEMENT COMMENCES ANY LITIGATION, PROCEEDING OR OTHER LEGAL ACTION IN CONNECTION WITH OR RELATING TO THIS AGREEMENT OR ANY MATTERS DESCRIBED OR CONTEMPLATED HEREIN, WITH RESPECT TO ANY OF THE MATTERS DESCRIBED OR CONTEMPLATED HEREIN, THE PARTIES TO THIS AGREEMENT HEREBY (I) AGREE THAT ANY LITIGATION, PROCEEDING OR OTHER LEGAL ACTION SHALL BE INSTITUTED IN A COURT OF COMPETENT JURISDICTION LOCATED IN NEW CASTLE COUNTY IN THE STATE OF DELAWARE, WHETHER A STATE OR FEDERAL COURT; (II) AGREE THAT IN THE EVENT OF ANY SUCH LITIGATION, PROCEEDING OR ACTION, SUCH PARTIES WILL CONSENT AND SUBMIT TO PERSONAL JURISDICTION IN ANY SUCH COURT DESCRIBED IN CLAUSE (I) OF THIS SECTION 4(a) AND TO SERVICE OF PROCESS UPON THEM IN ACCORDANCE WITH THE RULES AND STATUTES GOVERNING SERVICE OF PROCESS (IT BEING UNDERSTOOD THAT NOTHING IN THIS SECTION SHALL BE DEEMED TO PREVENT ANY PARTY FROM SEEKING TO REMOVE ANY ACTION TO A FEDERAL COURT IN IN NEW CASTLE COUNTY IN THE STATE OF DELAWARE); (III) AGREE TO WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY OBJECTION THAT THEY MAY NOW OR HEREAFTER HAVE TO THE VENUE OF ANY SUCH LITIGATION, PROCEEDING OR ACTION IN ANY SUCH COURT OR THAT ANY SUCH LITIGATION, PROCEEDING OR ACTION WAS BROUGHT IN AN INCONVENIENT FORUM; (IV) AGREE THAT SERVICE OF PROCESS IN ANY LEGAL PROCEEDING MAY BE MADE BY MAILING OF COPIES THEREOF TO SUCH PARTY AT ITS ADDRESS SET FORTH IN SECTION 11.3 OF THE ASSET PURCHASE AGREEMENT FOR COMMUNICATIONS TO SUCH PARTY; (V) AGREE THAT ANY SERVICE MADE AS PROVIDED HEREIN SHALL BE EFFECTIVE

AND BINDING SERVICE IN EVERY RESPECT; AND (VI) AGREE THAT NOTHING HEREIN SHALL AFFECT THE RIGHTS OF ANY PARTY TO EFFECT SERVICE OF PROCESS IN ANY OTHER MANNER PERMITTED BY LAW. EACH PARTY HERETO WAIVES THE RIGHT TO A TRIAL BY JURY IN ANY DISPUTE IN CONNECTION WITH OR RELATING TO THIS AGREEMENT OR ANY MATTERS DESCRIBED OR CONTEMPLATED HEREIN, AND AGREE TO TAKE ANY AND ALL ACTION NECESSARY OR APPROPRIATE TO EFFECT SUCH WAIVER.

- (b) Interpretation. For purposes of this Agreement, (a) the words “include,” “includes” and “including” shall be deemed to be followed by the words “without limitation”; (b) the word “or” is not exclusive; (c) the words “herein,” “hereof,” “hereby,” “hereto” and “hereunder” refer to this Assignment as a whole; and (d) unless the context otherwise requires, references herein to Sections and Exhibits mean the Sections of and Exhibits attached to this Assignment. The Parties have participated jointly in the negotiation and drafting of this Assignment, and any rule of construction or interpretation otherwise requiring this Assignment to be construed or interpreted against any Party by virtue of the authorship of this Assignment shall not apply to the construction and interpretation of this Assignment. The Exhibits referred to herein shall be construed with, and as an integral part of, this Assignment to the same extent as if they were set forth verbatim herein.
- (c) Amendment. This Agreement may be amended, modified or supplemented only by written agreement of all Parties.
- (d) Waiver. No failure or delay by a Party in enforcing any of such Party’s rights under this Agreement will be deemed to be a waiver of such rights. No single or partial exercise of a Party’s rights will be deemed to preclude any other or further exercise of such Party’s rights under this Agreement. No waiver of any of a Party’s rights under this Agreement will be effective unless it is in writing and signed by such Party.
- (e) Assignment. This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns, but neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any Party without the prior written consent of the other Party (not to be unreasonably withheld); provided that (i) either Party may assign its rights, interests and obligations under this Agreement to any Affiliate of such Party or to any Person who acquires all or substantially all of such Party’s assets, and (ii) subject to Section 7.11 of the Asset Purchase Agreement, Assignee may assign its rights, interests and obligations under this Agreement in their entirety, but not in part, to any Person to whom it transfers all or substantially all of the Acquired Assets. In the event that either Party

assigns its rights, interests and obligations hereunder without the consent of the other Party in accordance with the foregoing, the assigning Party shall promptly notify the other Party of such assignment and the identity of the assignee. This Agreement shall inure to the benefit of, and be binding upon, the Parties and their successors and permitted assigns. Any assignment of this Agreement or any of the rights, interests or obligations hereunder, in whole or in part, in contravention of this Section 4(d) shall be void ab initio.

- (f) Severability. The provisions of this Agreement shall be deemed severable, and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Agreement, or the application thereof to any Person or any circumstance, is invalid or unenforceable, (a) the Parties shall use reasonable best efforts to substitute a suitable and equitable provision therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision, and (b) the remainder of this Agreement and the application of such provision to other Persons or circumstances shall not be affected by such invalidity or unenforceability.
  
- (g) Counterparts. This Agreement may be executed in counterparts (including using any electronic signature covered by the United States ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable Law, e.g., [www.docusign.com](http://www.docusign.com)), and such counterparts may be delivered in electronic format, including by facsimile, email or other transmission method. Such delivery of counterparts shall be conclusive evidence of the intent to be bound hereby and each such counterpart, including those delivered in electronic format, and copies produced therefrom shall have the same effect as an originally signed counterpart. To the extent applicable, the foregoing constitutes the election of the Parties to invoke any Law authorizing electronic signatures. Minor variations in the form of the signature page, including footers from earlier versions of this Agreement, shall be disregarded in determining a Party's intent or the effectiveness of such signature. No Party shall raise the use the delivery of signatures to this Agreement in electronic format as a defense to the formation of a contract and each such Party forever waives any such defense.


[Remainder of page intentionally blank.]



IN WITNESS WHEREOF, this Patent Assignment Agreement has been duly executed and delivered by a duly authorized representative of each Party hereto as of the date first above written.

**ASSIGNORS:**


SAOL INTERNATIONAL LIMITED

By:   
Name: Kevin Insley  
Title: CEO

SAOL THERAPEUTICS RESEARCH LIMITED

By: \_\_\_\_\_  
Name: Paul Havenga  
Title: Director

SAOL INTERNATIONAL DEVELOPMENT LIMITED

By:   
Name: Kevin Insley  
Title: Director

*[Signature Page to Patent Assignment Agreement]*

**IN WITNESS WHEREOF**, this Patent Assignment Agreement has been duly executed and delivered by a duly authorized representative of each Party hereto as of the date first above written.

**ASSIGNORS:**

SAOL INTERNATIONAL LIMITED

By: \_\_\_\_\_  
Name: Kevin Insley  
Title: CEO

SAOL THERAPEUTICS RESEARCH LIMITED


By: \_\_\_\_\_  
Name: Paul Havenga  
Title: Director

SAOL INTERNATIONAL DEVELOPMENT  
LIMITED

By: \_\_\_\_\_  
Name: Kevin Insley  
Title: Director

*[Signature Page to Patent Assignment Agreement]*

SAOL INTERNATIONAL RESEARCH LIMITED


DocuSigned by:  
  
By: \_\_\_\_\_  
Name: Kevin Insley  
Title: Director

*[Signature Page to Patent Assignment Agreement]*

**PATENT**  
**REEL: 058975 FRAME: 0096**

**ASSIGNEE:**

AMNEAL PHARMACEUTICALS LLC

By:   
Name: Anastasios G. Konidaris  
Title: Chief Financial Officer

*[Signature Page to Patent Assignment Agreement]*

**PATENT**  
**REEL: 058975 FRAME: 0097**

**Exhibit A**  
**Patent Rights**

**U.S. Patents**

<b>Entity</b>	<b>Title</b>	<b>App. No.</b>	<b>Patent No.</b>
Saol International Limited	KIT AND METHOD OF REDUCING HUMAN ERROR DURING IMPLANTED INFUSTION PUMP REFILLING	15/935,894	10,434,248
Saol International Development Ltd.	BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME	15/426,136	10,076,506
Saol International Development Ltd.	BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME	14/935,003	9,597,304
Saol International Development Ltd.	BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME	13/661,800	9,180,108
Saol International Development Ltd.	BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME	16/105,615	10,420,740
Saol International Development Ltd.	BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME	16/544,128	10,813,900
Saol International Research Ltd.	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	16/524,664	10,792,262

**Patent Applications**

<b>Owner</b>	<b>Country</b>	<b>Title</b>	<b>Application No.</b>
Saol International Limited	US	SIMULTANEOUS USE OF IMAGING AND ENHANCED NEEDLES OR DEVICES TO IMPROVE SAFETY OF IMPLANTABLE PUMP REFILLS AND TROUBLESHOOTING	62/541,904
Saol International Limited	PCT	SIMULTANEOUS USE OF IMAGING AND ENHANCED NEEDLES OR DEVICES TO IMPROVE SAFETY OF IMPLANTABLE PUMP REFILLS AND TROUBLESHOOTING	PCT/US2018/045516
Saol International Limited	US	SIMULTANEOUS USE OF IMAGING AND ENHANCED NEEDLES OR DEVICES TO IMPROVE SAFETY OF IMPLANTABLE PUMP REFILLS AND TROUBLESHOOTING	16/637,114

Owner	Country	Title	Application No.
Saol International Limited	EP	SIMULTANEOUS USE OF IMAGING AND ENHANCED NEEDLES OR DEVICES TO IMPROVE SAFETY OF IMPLANTABLE PUMP REFILLS AND TROUBLESHOOTING	EP18843760.2
Saol International Limited	PCT	KIT AND METHOD OF REDUCING HUMAN ERROR DURING IMPLANTED INFUSION PUMP REFILLING	PCT/US2019/023891
Saol International Limited	US	KIT AND METHOD OF REDUCING HUMAN ERROR DURING IMPLANTED INFUSION PUMP REFILLING	17/041,886
Saol International Limited	EP	KIT AND METHOD OF REDUCING HUMAN ERROR DURING IMPLANTED INFUSION PUMP REFILLING	19774796.7
Saol International Limited	JP	KIT AND METHOD OF REDUCING HUMAN ERROR DURING IMPLANTED INFUSION PUMP REFILLING	2020-550804
Saol International Research Ltd.	PCT	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	PCT/US2020/034840
Saol International Research Ltd.	AU	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	2020323846
Saol International Research Ltd.	BR	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	BR1120220015917
Saol International Research Ltd.	CA	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	National Stage of PCT/US2020/034840
Saol International Research Ltd.	CN	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	National Stage of PCT/US2020/034840
Saol International Research Ltd.	EP	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	20847638.2
Saol International Research Ltd.	IN	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	National Stage of PCT/US2020/034840
Saol International Research Ltd.	JP	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	2022-506031

Owner	Country	Title	Application No.
Saol International Research Ltd.	MX	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	MX/a/2022/001139
Saol International Research Ltd.	RU	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	National Stage of PCT/US2020/034840
Saol International Research Ltd.	US	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	17/630,297
Saol International Research Ltd.	ZA	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	National Stage of PCT/US2020/034840
Saol International Research Ltd.	US	IMPROVED BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS	17/489,343
Saol International Development Ltd.	US	COMPOSITIONS AND METHODS OF ADMINISTERING BACLOFEN	17/525,298